Progesterone receptor expression is a marker for early stage breast cancer: Implications for progesterone receptor as a therapeutic tool and target

Cancer Letters

Volumn 258, Issue 2, 2007, Pages 253-261

  Coyle, Yvonne M ^a   Xie, Xian Jin ^a   Hardy, Daniel B ^b   Ashfaq, Raheela ^b   Mendelson, Carole R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Disease progression; Estrogen receptor; Progesterone receptor; Tumor stage

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PRIORITY JOURNAL; RISK; UNIVARIATE ANALYSIS;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ODDS RATIO; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 36048971615     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.09.011     Document Type: Article

References (77)

1. Harris J.R., Lippman M.E., Morrow M., and Osborne K. Diseases of the Breast. third ed. (2004), Lippincott Williams & Wilkins, Philadelphia, PA
2. Horwitz K.B., McGuire W.L., Pearson O.H., and Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189 (1975) 726-727
3. Kern W.D. Morphologic and clinical aspects of estrogen receptors in carcinoma of the breast. Surg. Gynecol. Obstet. 148 (1979) 240-242
4. Pichon M.-F., Pallud C., Brunet M., and Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 40 (1980) 3357-3360
5. Hull III D.F., Clark G.M., Osborne C.K., Chamness G.C., Knight III W.A., and McGuire W.L. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 43 (1983) 413-416
6. Brooks J.L., Ryan Jr. J.A., and Bauermeister D.E. Prognostic significance of hormone receptors in early recurrence of breast cancer. Am. J. Surg. 145 (1983) 599-603
7. Aamdal S., Bormer O., Jorgensen O., Host H., Eliassen G., Kaalhus O., et al. Estrogen receptors and long-term prognosis in breast cancer. Cancer 53 (1984) 2525-2529
8. Alanko A., Heinonen H., Scheinin T.M., Tolppanen E.-M., and Vihko R. Oestrogen and progesterone receptors and disease-free interval in primary breast cancer. Br. J. Cancer 50 (1984) 667-672
9. Crowe J.P., Gordon N.H., Hubay C.A., Pearson O.H., Marshall J.S., and Mansour E.G. The prognostic importance of estrogen receptor level for stage I breast cancer patients. Curr. Surg. (1984) 24-26 January-February
10. Butler J.A., Bretsky S., Menendez-Botet C., and Kinne D.W. Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 55 (1985) 1178-1181
11. Silvestrini R., Daidone M.G., Di Fronzo G., Morabito A., Valagussa P., and Bonadonna G. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res. Treat. 7 (1986) 161-169
12. Vollenweider-Zerarguui L., Barrelet L., Wong Y., Lemarchland-Beraud T., and Gomez F. The predictive value of estrogen and progesterone receptors' concentrations on clinical behavior of breast cancer in women. Cancer 57 (1986) 1176-1180
13. Hawkins R.A., White G., Bundred N.J., Dixon J.M., Miller W.R., Stewart H.J., et al. Prognostic significance of oestrogen and progestogen receptor activities in breast cancer. Br. J. Surg. 74 (1987) 1009-1013
14. Moot S.K., Peters G.N., and Cheek J.H. Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma. Cancer 60 (1987) 382-385
15. Ryden S., Ferno M., Borg A., Hafstrom L., Moller T., and Norgren A. Prognostic significance of estrogen and progesterone receptors in stage II breast cancer. J. Surg. Oncol. 37 (1988) 221-226
16. Fisher B., Redmond C., Fisher E.R., and Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06. J. Clin. Oncol. 6 (1988) 1076-1087
17. Maki H., and Hoehn J.L. Influence of estrogen receptors on survival and recurrence in patients with breast cancer without lymph node metastasis. Arch. Surg. 124 (1989) 377-380
18. Andry G., Suciu S., Pratola D., Sylvester R., Leclercq G., da Costa P.M., et al. Relation between estrogen receptor concentration and clinical and histological factors; their relative prognostic importance after radical mastectomy for primary breast cancer. Eur. J. Cancer Clin. Oncol. 25 (1989) 319-329
19. Costa S.D., Lange S., Klinga K., Merkle E., and Kauffmann M. Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer(results of the analysis of 670 patients with 11 years of follow-up. Eur. J. Cancer 38 (2002) 1329-1334
20. Moshin S.K., Weiss H., Havighurst T., Clark G.M., Berardo M., Roan H., et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod. Pathol. 17 (2004) 1545-1554
21. Donegan W.L. Prognostic factors. Stage and receptor status in breast cancer. Cancer 70 (1991) 1755-1764
22. Clark G.M., Osborne C.K., and McGuire W.L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol. 2 (1984) 1102-1109
23. Alghanem A.A., and Hussain S. The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer. J. Surg. Oncol. 31 (1986) 218-221
24. Allegra J.C., Lippman M.E., Thompson E.B., Simon R., Barlock A., Green L., et al. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 39 (1979) 1447-1454
25. Rich M.A., Furmanski P., and Brooks S.C. Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res. 38 (1978) 4296-4298
26. Hahnel R., Woodings T., and Vivian A.B. Prognostic value of estrogen receptors in primary breast cancer. Cancer 44 (1979) 671-675
27. Fisher B., Wickerham D.L., Brown A., and Redman C.K. Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance and relation to number of positive axillary nodes. J. Clin. Oncol. 1 (1983) 349-358
28. Fisher E.R., Sass R., and Fisher B. Pathologic findings from the national surgical adjuvant breast project. Cancer 59 (1987) 1554-1559
29. Chua D.Y.F., Pang M.W.Y., Rauff A., Aw S.-E., and Chan S.-H. Correlation of steroid receptors with histologic differentiation in mammary carcinoma. Cancer 56 (1985) 2228-2234
30. Knight III W.A., Livingston R.B., Gregory E.J., and McGuire W.L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37 (1977) 4669-4671
31. American Joint Committee on Cancer. AJCC Cancer Staging Manual. sixth ed. (2002), Springer, New York
32. Sismondi P., Aimone V., Genta F., Voglino G., Deltetto F., Giardina G., et al. Prognostic value of estrogen receptors determined by radiochemical vs. histochemical methods in breast cancer. Breast Cancer Res. Treat. 6 (1985) 67-73
33. Shek L., and Gdolphin W. Model for breast cancer survival: relative prognostic roles of axillary nodal status, TMN stage, estrogen receptor concentration, and tumor necrosis. Cancer Res. 48 (1988) 5565-5569
34. Pegoraro R., Karnan V., Nirmul D., and Joubert S.M. Estrogen and progesterone receptors in breast cancer among women of different racial groups. Cancer Res. 46 (1986) 2117-2120
35. Alexieva-Figusch J., Van Putten W.L.J., Blankenstein M.A., Blonk-van der Wijst J., and Klijn J.G.M. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 61 (1988) 758-768
36. Ruder A.M., Lubin F., Wax Y., Geier A., Alfundary E., and Chetrit A. Estrogen and progesterone receptors in breast cancer patients. Cancer 64 (1989) 196-202
37. Li C.I., Uribe D.J., and Daling J.R. Clinical characteristics of different histologic types of breast cancer. Brit. J. Cancer 93 (2005) 1046-1052
38. Hunter C.P., Redmond C.K., Chen V.W., Austin D.F., Greenberg R.S., Correa P., et al. Breast cancer: factors associated with stage at diagnosis in black and white women. J. Natl. Cancer Inst. 85 (1993) 1129-1137
39. Miller B.A., Hankey B.F., and Thomas T.L. Impact of socioeconomic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am. J. Epidemiol. 155 (2002) 534-545
40. Chen V.W., Correa P., Kurman P.J., Wu X.C., Eley J.W., Austin D., et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol. Biomarkers Prev. 3 (1994) 127-135
41. Elledge R.M., Clark G.M., Chamness G.C., and Osborne C.K. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J. Natl. Cancer Inst. 86 (1994) 705-712
42. Trock B.J. Breast cancer in African American women: epidemiology and tumor biology. Breast Cancer Res. Treat. 40 (1996) 11-24
43. Nixon A.J., Neuberg D., Hayes D.F., Gelman R., Connolly J.L., Schnitt S., et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J. Clin. Oncol. 12 (1994) 888-894
44. Albain K.S., Allred D.C., and Clark G.M. Breast cancer outcome and predictors of outcome: are there age differentials?. Monogr. Natl. Cancer Inst. 16 (1994) 35-42
45. Claus E.B. Genetic epidemiology of breast cancer in younger women. Monogr. Natl. Cancer Inst. 16 (1994) 49-53
46. Hunter C.P. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer 88 (2000) 1193-1202
47. Elmore J.G., Moceri V.M., Carter D., and Larson E.B. Breast carcinoma tumor characteristics in black and white women. Cancer 83 (1998) 2509-2525
48. Mandelblatt J., Andrews H., Kerner J., Zauber A., and Burnett W. Determinants of late stage diagnosis of breast and cervical cancer: the impact of age, race, social class, and hospital type. Am. J. Public Health 81 (1991) 646-649
49. Maehle B.O., Tretli S., Skjaerven R., and Thorsen T. Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesterone receptor status. Breast Cancer Res. Treat. 68 (2001) 159-169
50. Hall H.I., Coates R.J., Uhler R.J., Brinton L.A., Gammon M.D., Brogan D., et al. Stage of breast cancer in relation to body mass index and bra cup size. Int. J. Cancer 82 (1999) 23-27
51. Ross J.S., Fletcher J.A., Linette G.P., Stec J., Clark E., Ayers M., et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8 (2003) 307-325
52. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
53. Castle P.E., Ashfaq R., Ansari F., and Muller C.Y. Immmunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett. 229 (2005) 245-252
54. Federal Drug Administration (2004) QCA 510(k) submission. 510(k) summary Available from: (accessed July 12, 2007).
55. Wang S., Saboorian M.H., Frenkel E.P., Haley B.B., Siddiqui M.T., Gokaslan S., et al. Assessment of HER-2/neu status in breast cancer. Automated cellular imaging system (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am. J. Clin. Pathol. 116 (2001) 495-503
56. Institute of Medicine National Research Council. Fulfilling the Potential of Cancer Prevention and Early Detection (2001), The National Academies Press, Washington D.C.
57. Hilsenbeck S.G., Ravdin P.M., de Moor C.A., Chamness G.C., Osborne C.K., and Clark G.M. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Treat. Res. 52 (1998) 227-237
58. Carlson R.W., Brown E., Burstein H.J., Gradishar W.J., Hudis C.A., Loprinzi C., et al. NCCN task force report: adjuvant therapy for breast cancer. J. Natl. Compr. Canc. Netw. 4 (2006) S1-S26
59. Svahn T.H. Modest benefits of adjuvant chemotherapy in hormone receptor-positive breast cancer. Breast Cancer Online 9 (2006) 1-4
60. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Treat. Res. 51 (1998) 227-238
61. Lin V.C.L., Ng E.H., Aw S.E., Tan M.G., Ng E.H., Chan V.S., et al. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin. Cancer Res. 5 (1999) 395-403
62. Lin V.C.L., Ng E.H., Aw S.E., Tan M.G.K., Ng E.H.L., and Bay B.H. Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA. Mol. Endocrinol. 14 (2000) 348-358
63. Lin V.C.L., Eng A.S., Hen N.E., Ng E.H.L., and Chowdhury S.H. Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin. Cancer Res. 7 (2001) 2880-2886
64. Lin V.C.L., Jin R., Tan P.H., Aw S.E., Woon C.T., and Bay B.H. Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am. J. Clin. Pathol. 162 (2003) 1781-1787
65. Leo J.C.L., Wang S.M., Guo C.H., Aw S.E., Zhao Y., Li J.M., et al. Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor. Int. J. Cancer 117 (2005) 561-568
66. Hardy D.B., Janowski B.A., Corey D.R., and Mendelson C.R. Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression. Mol. Endocrinol. 20 (2006) 2724-2733
67. Wang D., and DuBois R.N. Cyclooxygenase-2: a potential target in breast cancer. Semin. Oncol. 31 (2004) 64-73
68. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
69. Shim V., Gauthier M.L., Sudilovsky D., et al. Cylcooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res. 63 (2003) 2347-2350
70. Perrone G., Santini D., Vincenzi B., Zagami M., La Cesa A., Bianchi A., et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 46 (2005) 561-568
71. Parret M.L., Harris R.E., Joarder F.S., Ross M.S., Clausen K.P., and Robertson F.M. Cyclooxygenase-2 expression in human breast cancer. Int. J. Oncol. 10 (1997) 503-507
72. Subbaramaiah K., Norton L., and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 277 (2002) 18649-18657
73. Cao Y., and Karin M. NF-κB in mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasia 8 (2003) 215-223
74. Janowski B.A., Kaihatsu K., Huffman K.E., Schwartz J.C., Ram R., Hardy D., et al. Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. Nat. Chem. Biol. 1 (2005) 210-215
75. Hunter K.W. Ezrin, a key component in tumor metastasis. Trends Mol. Med. 10 (2004) 201-204
76. Janowski B.A., Younger S.T., Hardy DB D.B., Ram R., Huffman K.E., and Corey D.R. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol. 3 (2007) 166-173
77. Leo J.C., Guo C., Woon C.T., Aw S.E., and Lin V.C.L. Glucocorticoid and mineralcorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 145 (2004) 1314-1321